ipo - Search News

Venture Global’s Stumble Reflects Chilly State of IPO Market

Wall Street Journal · 38m

Venture Global’s Stumble Reflects Chilly State of the IPO Market

Venture Global launched its initial public offering with a lofty goal: Raise up to $2.3 billion at a $110 billion valuation in the biggest stock-market debut since summer. The market had different plans.

Hosted on MSN · 1h

LNG pure-play Venture Global opens below its $25 per share IPO price

"The Trump administration has made very clear they support growing LNG exports," Venture CEO Mike Sabel told CNBC in an interview Friday.

Bloomberg L.P. · 4h

Venture Global Shares Indicated to Open About 6% Above IPO Price

Venture Global Inc. shares are indicated to open as much as 6% above their IPO price, after the natural gas exporter raised $1.75 billion in its first-time share sale.

Ascentage Pharma, Takeda and IPO

Bloomberg L.P. · 4h

Ascentage Pharma’s US Shares Climb After $126 Million IPO

Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut after pricing its $126.4 million initial public offering at a discount to its Asian stock.

Reuters on MSN · 20h

Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

Seeking Alpha on MSN · 5h

Takeda-backed Ascentage Pharma prices $126M U.S. IPO

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 per share,

8h

IPO market comeback: How recent major US listings fared

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

4h

3FPX, ARM : IPO Rebound In 2025? Here's What's Fueling The Boom,...

The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...

4h

2024 Year In Review: IPO Market Overview

In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...

FierceBiotech6h

‘A really rational IPO environment’: What does it takes for a biotech to go public now?

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

13h

Trump Partner Builds $1 Billion Stake From India Real Estate IPO

When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...

2h

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

2hon MSN

Venture Global Stock Drops Below Offering Price. The IPO Could Signal Shift in Energy Investing.

The transaction values the LNG company at $60 billion, instantly making it one of the largest U.S. energy businesses.

FierceBiotech11h

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results